In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite ...

Powerful white blood cells referred to as CD8 killer T cells enable the body to control infections and fight cancer. But when they become exhausted, they can become dysfunctional and ineffective.

Immune Checkpoint Blockade (ICB) has revolutionized the treatment of cancers like melanoma, but up to 60% of patients don't ...

Scientists uncover a new “recipe” that shows how exhausted T cells can be reprogrammed to regain their ability to attack tumors.

Colorectal cancer can be treated using immunotherapy approaches that use the immune cells to target cancer cells and induce the killing of those cancer cells. Some colorectal cancer types have been ...

On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...

Chimeric antigen receptor (CAR) T-cell therapy has shown efficacy in blood cancers — with six CAR T-cell products now approved by the US Food and Drug Administration (FDA) to treat six hematologic ...

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...